Related Experiment Video

Updated: Jul 14, 2026

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

Survival pathways in hypertrophy and heart failure: the gp130-STAT3 axis

P Fischer1, D Hilfiker-Kleiner

  • 1Dept. of Cardiology & Angiology, Medical School Hannover, Hannover, Germany.

Basic Research in Cardiology
|May 29, 2007
PubMed

Insights

Interleukin-6 (IL-6) and its receptor system are crucial in heart failure and after heart attacks. Understanding IL-6 signaling pathways offers insights into heart protection and disease progression.

Area of Science:

  • Cardiovascular Biology
  • Molecular Medicine
  • Immunology

Background:

  • Elevated circulating interleukin-6 (IL-6) and related cytokines are observed in congestive heart failure and post-myocardial infarction.
  • Serum IL-6 levels correlate with reduced functional capacity and serve as a prognostic indicator in these patients.
  • Impairment of the IL-6-glycoprotein (gp)130 receptor system is noted in failing human hearts, highlighting its role in cardiac pathophysiology.

Purpose of the Study:

  • To review the current understanding of IL-6 cytokines, the gp130 receptor, and STAT3 signaling in the heart.
  • To focus on the role of IL-6 signaling under physiological and pathophysiological stress conditions.
  • To explore the potential involvement of individual IL-6 cytokines in cardiac health and disease.

Main Methods:

  • Review of experimental studies on IL-6 cytokine signaling pathways in the heart.
  • Analysis of the phosphorylation and activation of the common receptor subunit gp130.
  • Examination of downstream signaling cascades including STAT1/3, SHP2-Ras-ERK, and PI3K-Akt.

Main Results:

  • The gp130 receptor system's components are impaired in failing human hearts.
  • IL-6 cytokine receptor activation triggers multiple downstream pathways (STAT1/3, SHP2-Ras-ERK, PI3K-Akt).
  • Gp130-mediated signaling influences cardiomyocyte survival, hypertrophy, extracellular matrix, and cardiac function.

Conclusions:

  • The gp130 receptor system and STAT3 signaling are key mediators in cardioprotection.
  • IL-6 signaling plays a significant role in cardiac pathophysiology under various stress conditions.
  • Further investigation into individual IL-6 cytokines may reveal specific therapeutic targets for heart disease.

More Related Videos

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes09:16

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

Generation and Expansion of Human Cardiomyocytes from Patient Peripheral Blood Mononuclear Cells05:38

Generation and Expansion of Human Cardiomyocytes from Patient Peripheral Blood Mononuclear Cells

Published on: February 12, 2021

Related Concept Videos

Cellular Adaptation II: Hypertrophy01:26

Cellular Adaptation II: Hypertrophy

Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...